Common-Size Income Statement

Difficulty: Beginner

Eli Lilly & Co., Common-Size Consolidated Income Statement

 
12 months ended Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Revenue 100.00    100.00    100.00    100.00    100.00   
Cost of sales -26.54    -26.65    -25.24    -25.15    -21.24   
Gross margin 73.46% 73.35% 74.76% 74.85% 78.76%
Research and development -23.09    -24.71    -24.03    -24.13    -23.93   
Marketing, selling, and administrative -28.81    -30.40    -32.73    -33.75    -30.83   
Acquired in-process research and development -4.86    -0.14    -2.68    -1.02    -0.25   
Asset impairment, restructuring, and other special charges -7.32    -1.80    -1.84    -2.39    -0.52   
Operating income 9.38% 16.30% 13.47% 13.56% 23.24%
Income related to termination of the exenatide collaboration with Amylin –    –    –    –    2.14   
Interest expense -0.98    -0.87    -0.81    -0.76    -0.69   
Interest income 0.73    0.51    0.44    0.62    0.52   
Venezuela charge –    -0.96    –    –    –   
Debt extinguishment loss –    –    -0.84    –    –   
Other income 0.48    0.92    1.71    1.88    0.28   
Other, net, income (expense) 0.23% -0.40% 0.50% 1.74% 2.25%
Income before income taxes 9.61% 15.90% 13.98% 15.30% 25.48%
Income taxes -10.50    -3.00    -1.91    -3.11    -5.21   
Net income (loss) -0.89% 12.90% 12.07% 12.19% 20.27%

Top